Brian Mech (PhD, MBA). Dr. Mech has spent nearly 25 years in leadership roles in med tech including more than 20 years in the ophthalmology space. Dr. Mech launched the Argus II Retinal Prothesis (Class III implantable) to treat blindness in Europe and North America and helped take Second Sight public on NASDAQ in November of 2014. He subsequently became CEO of Toronto-based eSight, helping the company to develop and launch its third-generation wearable to alleviate vision loss. Since moving to the Twin Cities in 2019, Dr. Mech has consulted on a number of innovative projects in the areas of obstructive sleep apnea, diabetes, epilepsy, depression, obesity, tinnitus, systemic inflammation, heart failure, pulmonary arterial hypertension, lymphatic drainage, vagus nerve stimulation, implantable smart pumps, remote patient monitoring, and healthcare IT. Dr Mech has a PhD in Materials Science and Plasma Physics from the University of Toronto (1997), and an MBA from UCLA’s Anderson School of Management (2003). Dr. Mech is also an inventor on over 50 US patents and more than 100 patents globally.